Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
AssigneeBeijing Synercare Pharma Tech Co., Ltd.
InventorsXiangyang CHEN, Yingxiang GAO, Chong LIU, Haihong NI, Mark MULVIHILL
Life of this patent
Estimating the term…
Abstract
Compounds of Formula I, as shown below and defined herein: and pharmaceutically acceptable salts, syntheses, intermediates, formulations, and methods of treating diseases including cancer, inflammation, and autoimmune disease mediated at least in part by Bruton's Tyrosine Kinase (BTK).
Claims20
A compound according to Formula I:
- wherein:
- A is selected from C3-12cycloalkyl, C3-12heterocycloalkyl, C3-12aryl, or C3-12heteroaryl, any of which is optionally substituted with G1 substituents;
- B1 is selected from C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G2 substituents;
- B2 is selected from C0-12alkyl, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G3 substituents;
- L1 is selected from —C0-2alkyl-, —CR5R6—, —C0-3alkyl(R5)(OH)—, —C(O)—, —CH2O—, —OCH2—, —CF2—, —SCR5R6—, —CR5R6S—, —N(R5)—, —N(R5)C(O)—, —C(O)N(R5)—, —N(R5)C(O)N(R6)—, —O—, —S—, —S(O)m1—, —N(R5)S(O)m1—, or —S(O)m1N(R5)—;
- L2 is selected from —C0-4alkyl-, —C(O)—, —N(R7)—, —N(R7)C(O)—, or —N(R7)S(O)m2—;
- X is selected from C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G4 substituents;
- Y is selected from —C(O)—, —N(R8)—, —N(R8)C(O)—, —S(O)m3—, or —N(R8)S(O)m3—;
- R1 is selected from —C(O)R9, —C(O)NR9R10, —C(O)OR9, C1-4alkynyl, OR9, S(O)m4R9R10, or —CN;
- R2, R3, and R4 are each independently selected from C0-12alkyl, —CN, halo, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G5 substituents;
- R5, R6, R7, R8, R9, and R10 are each independently selected from C0-12alkyl, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, or heteroaryl-C3-12heterocycloalkyl-, any of which is optionally substituted with G6 substituents;
- G1, G2, G3, G4, G5, and G6 are each independently selected from one or more of C0-12alkyl, —C2-12alkenyl, —C2-12alkynyl, D, -CD3, —OCD3, halo, —CN, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —P(O)C0-3 alkyl, —PO(OR11)2, —PO(OR11)R12, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12alkyl-, aryl-C3-12cycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C0-12alkyl-, heteroaryl-C3-12cycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C0-6alkylOR11, —OC(O)NR11R12, —C(O)OR11, —C(O)NR11R12, —C(O)R11, —NR11R12, —NR11C(O)R12, —NR13C(O)NR11R12, —S(O)m5R11, and —NR11S(O)m5R12, any of which is optionally substituted with independently selected Q1 substituents;
- Q1 is selected from one or more of C0-12alkyl-, —C2-12alkenyl, —C2-12alkynyl, D, halo, —CN, -CD3, —OCD3, -oxo-, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —PO(OR14)2, —PO(OR14)R15, NR14R15, —C(O)NR14OH, —C0-6alkylOR14, aryl-C0-12alkyl-, heteroaryl-C0-12alkyl-, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12cycloalkyl-, heteroaryl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12cycloalkyl-, C3-12cycloalkyl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12heterocycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C(O)—C(O)NR14R15, —C(O)—C(O)OR14, —OC(O)R14, —NR14C(O)R15, —NR14S(O)m6R15, —(CR15R16)n1C(O)R14, —(CR15R16)n1C(O)OR14, —(CR15R16)n1C(O)NR14R17, (CR15R16)n1S(O)m6NR14R17, —(CR15R16)n1NR14R17, —(CR15R16)n1OR14, —(CR15R16)n1S(O)m6R14, —NR16C(O)NR14R15, and —NR16S(O)m6NR14R15, any of which is optionally substituted with independently selected E1 substituents;
- E1 is selected from one or more of C0-12alkyl-, —C2-12alkenyl, —C2-12alkynyl, D, halo, —CN, -oxo-, -CD3, —OCD3, —CF3, —OCF3, —OCHF2, —NO2, —B(OH)2, —PO(OR18)2, —PO(OR18)R19, —C(O)NR18OH, —C(O)NR18R19, —C0-12alkylOR18, aryl-C0-12alkyl-, heteroaryl-C0-12alkyl-, C3-12cycloalkyl-C0-12alkyl-, C3-12heterocycloalkyl-C0-12alkyl-, aryl-C0-12cycloalkyl-, heteroaryl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12cycloalkyl-, C3-12cycloalkyl-C3-12cycloalkyl-, C3-12heterocycloalkyl-C3-12heterocycloalkyl-, aryl-C3-12heterocycloalkyl-, heteroaryl-C3-12heterocycloalkyl-, —C(O)—C(O)NR18R19, —C0-12alkylC(O)OR18, —C(O)—C(O)OR18, —OC(O)R18, —NR18C(O)R19, —NR18C(O)OR19, —NR18S(O)m7R19, —(CR19R20)n2C(O)R18, —(CR19R20)n2C(O)OR18, —(CR19R20)n2C(O)NR18R21, —(CR19R20)n2S(O)m7NR18R21, —(CR19R20)n2NR18R21, —(CR19R20)n2OR18, —(CR19R20)n2S(O)m7R18, —NR20C(O)NR18R19, and —NR20S(O)m7NR18R19 substituents;
- R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, and R21 are each independently selected from H, C1-6alkyl-, C3-8cycloalkyl-C0-6alkyl-, C3-8heterocycloalkyl-C0-6alkyl-, aryl-C0-6alkyl-, aryl-C3-8cycloalkyl-, aryl-C3-8heterocycloalkyl-, heteroaryl-C1-6alkyl-, heteroaryl-C3-8cycloalkyl-, or heteroaryl-C3-8heterocycloalkyl-;
- R3 and R4 are taken together with the carbon atoms to which they are attached to form a 3-12 membered partially saturated or unsaturated ring, wherein said ring optionally includes one or more additional heteroatoms selected from O, N, or S(O)m8;
- m1, m2, m3, m4, m5, m6, m7, m8, n1, and n2 are each independently selected from 0, 1, or 2;
- or a pharmaceutically acceptable salt, solvate or a prodrug thereof.
A pharmaceutical composition comprising the compound or salt of any one of the compounds of Formula I, formulated with or without one or more pharmaceutical carriers.
A method for the treatment of at least one of cancer, chronic inflammation, and autoimmune disease mediated at least in part by BTK comprising administering to a subject in need thereof a therapeutically effective amount of a compound or salt of the compound of Formula I.
A compound selected from one or more of:
- 6-(3-acrylamidophenyl)-2-(4-phenoxyphenyl)nicotinamide;
- 2-(4-phenoxyphenyl)-6-(piperidin-4-yl)nicotinamide;
- 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)nicotinamide;
- 2-(4-phenoxyphenyl)-6-(piperazin-1-yl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-phenoxyphenyl)nicotinamide;
- 6-(1-acryloylpyrrolidin-3-yl)-2-(4-phenoxyphenyl)nicotinamide;
- 6-(4-acrylamidophenyl)-2-(4-phenoxyphenyl)nicotinamide;
- 6-(1-acryloylpiperidin-3-yl)-2-(4-phenoxyphenyl)nicotinamide;
- 6-(4-acrylamidopiperidin-1-yl)-2-(4-phenoxyphenyl)nicotinamide;
- 6-(3-acrylamidopyrrolidin-1-yl)-2-(4-phenoxyphenyl)nicotinamide;
- 1-(1-acryloylpiperidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 1-(1-acryloylpiperidin-4-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 1-(1-acryloylpyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 1-(azetidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 1-(1-acryloylazetidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 1-(4-acrylamidophenyl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 1-(3-aminophenyl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 1-(3-acrylamidophenyl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- (S)-1-(1-acryloylpyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- (R)-1-(1-acryloylpyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 2-(1-acryloylpiperidin-4-yl)-4-(4-phenoxyphenyl)pyrimidine-5-carboxamide;
- 2-(1-acryloylpyrrolidin-3-yl)-4-(4-phenoxyphenyl)pyrimidine-5-carboxamide;
- 6-(1-acryloylpyrrolidin-3-yl)-2-(4-phenoxyphenyl)pyridine-3-carboxamide;
- 6-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)pyridine-3-carbonitrile
- (E)-6-(4-(4-(dimethylamino)but-2-enoyl)piperazin-1-yl)-2-(4-phenoxyphenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-phenoxyphenyl)pyridine-3-carboxylic acid
- 6-(4-acryloylpiperazin-1-yl)-2-(4-(4-cyanophenoxy)phenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-(0)phenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(3-methoxy-4-methylphenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-fluoro-3-methoxyphenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-6′-phenoxy-2,3′-bipyridine-3-carboxamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-(pyridin-2-yloxy)phenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-chlorophenyl)nicotinamide;
- 1-(1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-(3-fluorophenoxy)phenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(3-fluoro-4-phenoxyphenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-(4-fluorophenoxy)phenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-(2-fluorophenoxy)phenyl)nicotinamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(2-fluoro-4-phenoxyphenyl)nicotinamide;
- 2-(1-acryloylpiperidin-3-yl)-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
- 2-(1-acryloylpyrrolidin-3-yl)-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
- 2-(1-acryloylpiperidin-3-yl)-4-(4-phenoxyphenyl)oxazole-5-carboxamide;
- 2-(1-acryloylpyrrolidin-3-yl)-4-(4-phenoxyphenyl)oxazole-5-carboxamide;
- 2-(1-acryloylpyrrolidin-3-yl)-5-(4-phenoxyphenyl)thiazole-4-carboxamide;
- 2-(1-acryloylpiperidin-3-yl)-5-(4-phenoxyphenyl)thiazole-4-carboxamide;
- 2-(1-acryloylpiperidin-4-yl)-4-(4-phenoxyphenyl)oxazole-5-carboxamide;
- 2-(4-acryloylpiperazin-1-yl)-N-methyl-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
- 2-(1-acryloylpyrrolidin-3-yl)-5-(4-phenoxyphenyl)oxazole-4-carboxamide;
- 2-(1-acryloylpiperidin-4-yl)-5-(4-phenoxyphenyl)thiazole-4-carboxamide;
- 2-(4-acryloylpiperazin-1-yl)-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
- 2-(1-acryloylpiperidin-4-yl)-4-(4-phenoxyphenyl)thiazole-5-carboxamide;
- (E)-1-(1-(2-cyano-3-cyclopropylacryloyl)azetidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 1-cyclopentyl-5-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 2-(1-acryloylpiperidin-3-yl)-5-(4-phenoxyphenyl)oxazole-4-carboxamide;
- 5-(1-acryloylpiperidin-4-yl)-4′-phenoxybiphenyl-2-carboxamide;
- 5-(1-acryloylpiperidin-4-yl)-1-(4-phenoxyphenyl)-1H-pyrazole-3-carboxamide;
- 5-(4-acryloylpiperazin-1-yl)-4′-phenoxybiphenyl-2-carboxamide;
- 6-(1-acryloylpiperidin-4-yl)-2-(4-(hydroxy(phenyl)methyl)phenyl)nicotinamide;
- (E)-1-(1-(2-cyanobut-2-enoyl)azetidin-3-yl)-3-(4-phenoxyphenyl)-1H-pyrazole-4-carboxamide;
- 6-(4-acryloylpiperazin-1-yl)-2-(4-((4,4-difluorocyclohexyl)oxy)phenyl)nicotinamide;
- 6-(1-acryloylpiperidin-4-yl)-2-(4-(phenylcarbamoyl)phenyl)nicotinamide;
- 6-cyclohexyl-2-(4-phenoxyphenyl)nicotinamide;
- 2-(4-phenoxyphenyl)-6-(4-(vinylsulfonyl)piperazin-1-yl)nicotinamide;
- 2-(4-phenoxyphenyl)-6-(1-(vinylsulfonyl)piperidin-4-yl)nicotinamide;
- 1-(1-acryloylpiperidin-3-yl)-3-(4-(phenylcarbamoyl)phenyl)-1H-pyrazole-4-carboxamide;
- 1-(1-acryloylpiperidin-3-yl)-3-(4-((4-(trifluoromethyl)pyridin-2-yl)carbamoyl)phenyl)-1H-pyrazole-4-carboxamide;
- 6-(4-acrylamidophenyl)-2-(4-(phenylcarbamoyl)phenyl) nicotinamide;
- 6-(4-acrylamidophenyl)-2-(4-((4-(trifluoromethyl)pyridin-2-yl)carbamoyl)phenyl) nicotinamide;
- 1-(1-acryloylpiperidin-3-yl)-3-(4-(hydroxy(phenyl)methyl)phenyl)-1H-pyrazole-4-carboxamide;
- 1-(1-acryloylpiperidin-3-yl)-3-(4-(methyl(phenyl)amino)phenyl)-1H-pyrazole-4-carboxamide;
- 6-(4-acrylamidophenyl)-2-(4-(1-hydroxy-1-phenylethyl)phenyl)nicotinamide;
- 6-(4-acrylamidophenyl)-2-(4-(difluoro(phenyl)methyl)phenyl)nicotinamide;
- 1-(1-acryloylpiperidin-3-yl)-3-(4-(phenylsulfonyl)phenyl)-1H-pyrazole-4-carboxamide;
- 6-(4-acrylamidophenyl)-2-(4-(phenylsulfonyl)phenyl) nicotinamide;
- or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.